InTouch Indexed in Medline and Index Medicus

Publication
Article
OncologyONCOLOGY Vol 16 No 6
Volume 16
Issue 6

InTouch magazine, a sister publication of ONCOLOGY and Oncology News International, has been selected by the National Library of Medicine to be indexed and included in Index Medicus and Medline. InTouch is published by PRR for cancer patients and their families.

InTouch magazine, a sister publicationof ONCOLOGY and Oncology News International, has been selected by the NationalLibrary of Medicine to be indexed and included in Index Medicus and Medline. InTouch is published by PRR for cancer patients and their families.

"It’s a real tribute to the editorial quality of InTouch," said Steven T. Rosen, MD. Dr. Rosen, director of the Robert H.Lurie Comprehensive Cancer Center, serves as medical editor-in-chief for InTouch,which just celebrated its third year of publication.

The National Library of Medicine looks to an advisorycommittee—the Literature Selection Technical Review Committee—to choosejournals and other publications for citation. Composed of authoritiesknowledgeable in the field of biomedicine, the committee includes physicians,researchers, educators, editors, health science librarians, and historians whoreview and recommend titles for indexing. The databases in the Medlars system inwhich InTouch will appear are Index Medicus and Medline. These databases areavailable online internationally.

"We’re delighted that the NLM has recognized the integrity and valueof the information in InTouch," said Dr. Rosen. "Their endorsementfurthers our mission, which is to give patients and their loved ones the mostauthoritative and up-to-date information on cancer prevention and treatment sothat they can be better informed about their health care."

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
Related Content